Bio-Techne adds Dr. Amy E. Herr to its Board of Directors

MINNEAPOLIS - Bio-Techne (NASDAQ:TECH) Corporation (NASDAQ: TECH), a global life sciences company valued at $11.45 billion, has announced the appointment of Dr. Amy E. Herr as an independent director on its Board of Directors. Dr. Herr began her tenure on Monday, succeeding retiring director Dr. Roeland Nusse. According to InvestingPro data, the company maintains strong financial health with an impressive current ratio of 4.56, indicating robust liquidity management.

Dr. Herr, a Chancellor’s Professor of Bioengineering at the University of California, Berkeley, also serves as the Vice President of the Chan Zuckerberg Biohub Network. With a Ph.D. in Mechanical Engineering from Stanford University and a B.S. in Engineering & Applied Science from Caltech, she has held several prestigious roles in academia and industry. Her experience includes founding the Bakar BioEnginuity Hub at UC Berkeley and serving on the National Advisory Council for Biomedical Imaging and Bioengineering for the National Institutes of Health.

The completion of Dr. Herr’s appointment marks the end of a two-year search by Bio-Techne’s Board of Directors for successors to retiring members. Kim Kelderman, President and CEO of Bio-Techne, expressed enthusiasm about Dr. Herr’s deep biological and engineering experience aligning with the company’s strategic direction. Chairman Bob Baumgartner also highlighted Dr. Herr’s significant scientific experience, particularly in bioengineering, as a valuable addition to the board as the company expands its proteomic analytical instrument business.

Bio-Techne, with a portfolio of hundreds of thousands of products, generated approximately $1.2 billion in net sales in fiscal 2024 and employs around 3,100 people globally. The company specializes in providing tools and bioactive reagents for research and clinical diagnostic communities, supporting scientific investigations into biological processes and diseases, drug discovery, and clinical diagnostics. InvestingPro analysis reveals the company maintains a strong gross profit margin of 66% and has consistently paid dividends for 17 consecutive years, demonstrating operational efficiency and commitment to shareholder returns.

This board appointment, based on a press release statement, comes as part of Bio-Techne’s ongoing efforts to strengthen its leadership and strategic capabilities in the life sciences industry. For investors seeking deeper insights, InvestingPro offers comprehensive analysis with 8 additional ProTips and a detailed Pro Research Report, available as part of the subscription covering 1,400+ top US stocks.

In other recent news, Bio-Techne Corporation has seen a series of developments. The company reported a 4% year-over-year organic revenue growth in its first quarter for Fiscal Year 2025, with revenues reaching $289.5 million. The company’s adjusted earnings per share (EPS) saw a slight increment to $0.42 from the previous year’s $0.41.

In a significant legal victory, Bio-Techne won a patent case against Miltenyi Biotec, with the Cologne Regional Court ruling in favor of Bio-Techne. The company has been forging strategic alliances, partnering with Waters Corporation (NYSE:WAT) to enhance biotherapeutic development processes, and with Leader Life Sciences to distribute its comprehensive portfolio throughout the Gulf Cooperation Council countries.

Bio-Techne also granted its Executive Vice President and Chief Financial Officer, James Hippel, a one-time award of 34,634 restricted stock units (RSUs) as a retention incentive. Finally, Baird, a financial services firm, increased its price target for Bio-Techne from $82 to $84, maintaining an Outperform rating after the company’s strong quarterly results.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.